Monday, October 09, 2023 4:35:52 PM
https://www.otcmarkets.com/stock/IMUX/news/story?e&id=2652472
Recent IMUX News
- Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update • PR Newswire (US) • 05/01/2024 10:30:00 AM
- Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation • PR Newswire (US) • 04/30/2024 10:30:00 AM
- Immunic to Host MS R&D Day and Participate in Investor Conferences in April • PR Newswire (US) • 04/04/2024 10:30:00 AM
- Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States • PR Newswire (US) • 03/20/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:05:28 PM
- Immunic to Participate in Investor and Scientific Conferences in March • PR Newswire (US) • 03/07/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:52:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:51:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:51:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 02:50:05 AM
- Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 • PR Newswire (US) • 02/29/2024 11:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 11:38:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:35:56 AM
- Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/22/2024 11:30:00 AM
- Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update • PR Newswire (US) • 02/15/2024 11:30:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:05:39 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:47:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:36:14 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/05/2024 01:30:32 PM
- Immunic to Participate in Investor and Scientific Conferences in February • PR Newswire (US) • 02/01/2024 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/24/2024 10:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:07:16 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM